HUP1000069A2 - New salts for the preparation of pharmaceutical composition - Google Patents
New salts for the preparation of pharmaceutical compositionInfo
- Publication number
- HUP1000069A2 HUP1000069A2 HU1000069A HUP1000069A HUP1000069A2 HU P1000069 A2 HUP1000069 A2 HU P1000069A2 HU 1000069 A HU1000069 A HU 1000069A HU P1000069 A HUP1000069 A HU P1000069A HU P1000069 A2 HUP1000069 A2 HU P1000069A2
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical composition
- new salts
- salts
- new
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1000069A HUP1000069A2 (en) | 2010-02-02 | 2010-02-02 | New salts for the preparation of pharmaceutical composition |
CN2011800153251A CN102858762A (en) | 2010-02-02 | 2011-02-02 | Novel salts for the manufacture of pharmaceutical compositions |
PCT/HU2011/000014 WO2011110876A1 (en) | 2010-02-02 | 2011-02-02 | Novel salts for the manufacture of pharmaceutical compositions |
EA201290726A EA022496B1 (en) | 2010-02-02 | 2011-02-02 | Polymorphous form of dabigatran etexilate hydrochloride |
ZA2012/06254A ZA201206254B (en) | 2010-02-02 | 2012-08-20 | Novel salts for the manufacture of pharmaceutical compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1000069A HUP1000069A2 (en) | 2010-02-02 | 2010-02-02 | New salts for the preparation of pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
HU1000069D0 HU1000069D0 (en) | 2010-04-28 |
HUP1000069A2 true HUP1000069A2 (en) | 2012-05-02 |
Family
ID=89989543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU1000069A HUP1000069A2 (en) | 2010-02-02 | 2010-02-02 | New salts for the preparation of pharmaceutical composition |
Country Status (5)
Country | Link |
---|---|
CN (1) | CN102858762A (en) |
EA (1) | EA022496B1 (en) |
HU (1) | HUP1000069A2 (en) |
WO (1) | WO2011110876A1 (en) |
ZA (1) | ZA201206254B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
WO2012027543A1 (en) * | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
US9006448B2 (en) | 2010-12-06 | 2015-04-14 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and its salts |
CN102558153A (en) * | 2012-02-08 | 2012-07-11 | 北京阜康仁生物制药科技有限公司 | Novel pharmaceutical salt of dabigatran etexilate and preparation method thereof |
EP2631234A1 (en) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Solid forms of dabigatran etexilate mesylate and processes for their preparation |
WO2013144971A1 (en) * | 2012-03-27 | 2013-10-03 | Cadila Healthcare Limited | New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them |
CN102633777B (en) * | 2012-03-31 | 2014-04-16 | 天津药物研究院 | Dabigatran etexilate 2-ketoglutarate as well as preparation method and application thereof |
WO2013150545A2 (en) | 2012-04-02 | 2013-10-10 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
CN103539779B (en) * | 2012-07-13 | 2016-12-21 | 四川海思科制药有限公司 | A kind of hydroxyl-substituted sulfonate of dabigatran etcxilate and its production and use |
EP2872499A1 (en) * | 2012-07-16 | 2015-05-20 | Interquim, S.A. | Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates |
EP2900652A2 (en) | 2012-09-28 | 2015-08-05 | Ranbaxy Laboratories Limited | Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof |
IN2015DN02616A (en) | 2012-09-28 | 2015-09-18 | Ranbaxy Lab Ltd | |
CN103864756B (en) * | 2012-12-11 | 2018-06-15 | 四川海思科制药有限公司 | Fourth disulfonic acid dabigatran etcxilate and its preparation method and application |
WO2014178017A1 (en) | 2013-04-30 | 2014-11-06 | Ranbaxy Laboratories Limited | Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard |
EP2835370A1 (en) | 2013-08-08 | 2015-02-11 | Medichem, S.A. | New crystals of dabigatran etexilate mesylate |
CN104418840A (en) * | 2013-09-05 | 2015-03-18 | 天津汉瑞药业有限公司 | Dabigatran etexilate mesylate anhydrous compound |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
CN104892574A (en) * | 2014-03-04 | 2015-09-09 | 浙江海正药业股份有限公司 | Dabigatran etexilate mesylate crystal forms, preparation methods and uses thereof |
CN108947966A (en) * | 2014-04-04 | 2018-12-07 | 江苏天士力帝益药业有限公司 | Dabigatran etcxilate mesylate novel crystal forms and preparation method thereof |
EP3169677A1 (en) * | 2014-07-18 | 2017-05-24 | OLON S.p.A. | Crystalline compounds of dabigatran etexilate |
CN105348260A (en) * | 2014-08-19 | 2016-02-24 | 天津药物研究院 | Dabigatran etexilate hydrobromide, preparation method and applications thereof |
CN106554370A (en) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | Dabigatran derivant containing phosphate ester and its production and use |
CN116621815A (en) * | 2023-07-21 | 2023-08-22 | 成都苑东生物制药股份有限公司 | Industrial preparation method of dabigatran etexilate mesylate |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE121699A1 (en) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN |
DE10337697A1 (en) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts |
DE10339862A1 (en) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis |
DE102005020002A1 (en) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New hexyloxycarbonylamino-imino-methyl-phenylamino-methyl-benzimidazole-pyridine-propionic acid-ethyl ester salts such as hydrochloride useful for the prophylaxis of vein thrombosis and stroke |
DE102005025728A1 (en) | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester |
DE102005061623A1 (en) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improved process for the preparation of 4- (benzimidazolylmethylamino) -benzamidines and their salts |
BRPI0715492A2 (en) * | 2006-07-17 | 2013-03-19 | Boehringer Ingelheim Int | use of direct thrombin inhibitors |
US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
DE102006054005A1 (en) | 2006-11-16 | 2008-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl |
CN100556642C (en) * | 2007-06-06 | 2009-11-04 | 中国科学院化学研究所 | The regulate and control method of aliphatic poly adipic acid fourth diester material degradation performance |
-
2010
- 2010-02-02 HU HU1000069A patent/HUP1000069A2/en not_active IP Right Cessation
-
2011
- 2011-02-02 WO PCT/HU2011/000014 patent/WO2011110876A1/en active Application Filing
- 2011-02-02 EA EA201290726A patent/EA022496B1/en not_active IP Right Cessation
- 2011-02-02 CN CN2011800153251A patent/CN102858762A/en active Pending
-
2012
- 2012-08-20 ZA ZA2012/06254A patent/ZA201206254B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011110876A8 (en) | 2012-07-05 |
ZA201206254B (en) | 2013-10-30 |
CN102858762A (en) | 2013-01-02 |
WO2011110876A1 (en) | 2011-09-15 |
EA022496B1 (en) | 2016-01-29 |
HU1000069D0 (en) | 2010-04-28 |
EA201290726A1 (en) | 2013-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP1000069A2 (en) | New salts for the preparation of pharmaceutical composition | |
HK1246170A1 (en) | Pharmaceutical composition | |
IL225457A0 (en) | Pharmaceutical composition | |
SI2619182T1 (en) | Pharmaceutical composition | |
FI4159204T3 (en) | Novel pharmaceutical composition | |
PT2579858E (en) | Ivabradine-containing pharmaceutical composition | |
ZA201301920B (en) | Pharmaceutical composition | |
EP2702989A4 (en) | Stable pharmaceutical composition | |
GB201010453D0 (en) | Pharmaceutical composition | |
ZA201207375B (en) | Stabilized pharmaceutical composition | |
HRP20160901T1 (en) | Pharmaceutical composition containing solifenacin | |
EP2668852A4 (en) | Composition for oral administration | |
PT2594266E (en) | Pharmaceutical solid compositions containing ibuprofen salts | |
GB201001911D0 (en) | Pharmaceutical composition | |
HK1188959A1 (en) | Fosfomycin pharmaceutical composition | |
ZA201308414B (en) | Solid pharmaceutical composition | |
EP2543373A4 (en) | Compound pharmaceutical composition of levoamlodipine | |
HU1000624D0 (en) | Novel salts skitable for the preparation of pharmaceutical compositions | |
GB201019775D0 (en) | Pharmaceutical composition | |
HU1000006D0 (en) | Improved pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of definitive patent protection due to non-payment of fees |